Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 2/20 | 0.70 |
| ▸ | ITGAV | P06756 | 2/20 | 0.70 |
| ▸ | ITGB5 | P18084 | 2/20 | 0.70 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.70 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.70 |
| ▸ | PLAU | P00749 | 2/20 | 0.60 |
| ▸ | KLKB1 | P03952 | 6/20 | 0.58 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.56 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.56 |
| ▸ | ELANE | P08246 | 4/20 | 0.53 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.53 |
| ▸ | TCF4 | P15884 | 1/20 | 0.53 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.53 |
| ▸ | ACE | P12821 | 1/20 | 0.52 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22342257 | 0.93 | ITGAV (0.59) | ITGB3ITGAVITGB5ITGB1ITGA5 | |
| SCHEMBL22341392 | 0.92 | ITGAV (0.60) | ITGB3ITGAVITGB5ITGB1ITGA5 | |
| SCHEMBL22342265 | 0.88 | KEAP1 (0.62) | ITGB3ITGAVITGB5ITGB1ITGA5 | |
| SCHEMBL22342227 | 0.87 | KEAP1 (0.58) | ITGB3ITGAVITGB5ITGB1ITGA5 | |
| SCHEMBL22342183 | 0.87 | ITGAV (0.63) | ITGB3ITGAVITGB5ITGB1ITGA5 | |
| SCHEMBL22342182 | 0.87 | ITGAV (0.62) | ITGB3ITGAVITGB5ITGB1ITGA5 | |
| SCHEMBL22341445 | 0.86 | ITGAV (0.53) | ITGB3ITGAVITGB5ITGB1ITGA5 | |
| SCHEMBL22342253 | 0.86 | ITGB3 (0.65) | ITGB3ITGAVITGB5ITGB1ITGA5 | |
| SCHEMBL22342251 | 0.86 | ITGB3 (0.64) | ITGB3ITGAVITGB5ITGB1ITGA5 | |
| SCHEMBL22342181 | 0.83 | ITGB3 (0.61) | ITGB3ITGAVITGB5ITGB1ITGA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200255478-A1 | NOVEL COMPOUNDS ACTIVATING THE NRF2 PATHWAY | ALMIRALL SA (ES) | 2020-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200255478-A1 | NOVEL COMPOUNDS ACTIVATING THE NRF2 PATHWAY | KEAP1, NFE2L2, HMOX1 | ITGB3 4873/4885ITGAV 4854/4885ITGB5 4807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.